Ionis Pharmaceuticals Files 8-K on Financials
Ticker: IONS · Form: 8-K · Filed: Nov 6, 2024 · CIK: 874015
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: IONS
TL;DR
IONIS filed an 8-K for financial updates, check for details.
AI Summary
On November 6, 2024, Ionis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This filing indicates that Ionis Pharmaceuticals is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not inherently present new risks.
Key Players & Entities
- IONIS PHARMACEUTICALS INC (company) — Registrant
- November 6, 2024 (date) — Date of earliest event reported
- 2855 Gazelle Court Carlsbad , CA 92010 (address) — Principal Executive Offices
- ISIS PHARMACEUTICALS INC (company) — Former Company Name
FAQ
What specific financial information is being reported in this 8-K filing?
The provided excerpt states the filing concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail specific figures.
When was the earliest event reported in this filing?
The earliest event reported was on November 6, 2024.
What is the principal executive office address for Ionis Pharmaceuticals, Inc.?
The principal executive office is located at 2855 Gazelle Court, Carlsbad, CA 92010.
What was the former name of Ionis Pharmaceuticals, Inc.?
The former name was ISIS PHARMACEUTICALS INC.
Under which section of the SEC Act is this 8-K filed?
This is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 609 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-11-06 11:15:52
Filing Documents
- ef20038192_8k.htm (8-K) — 27KB
- ef20038192_ex99-1.htm (EX-99.1) — 409KB
- image0.jpg (GRAPHIC) — 24KB
- 0001140361-24-045370.txt ( ) — 629KB
- ions-20241106.xsd (EX-101.SCH) — 4KB
- ions-20241106_lab.xml (EX-101.LAB) — 21KB
- ions-20241106_pre.xml (EX-101.PRE) — 16KB
- ef20038192_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On November 6, 2024, Ionis Pharmaceuticals, Inc. (the " Company ") issued a press release announcing the Company's financial results for the quarter ended September 30, 2024. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (" GAAP "), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equity awards and the related tax effects. The Company is presenting pro forma information excluding non-cash compensation expense and the related tax effects because the Company believes it better enables financial statement users to assess and compare its historical performance and project its future operating results and cash flows. A copy of the release is furnished with this report as an exhibit pursuant to "Item 2.02. Results of Operations and Financial Condition" of Form 8-K in accordance with SEC Release Nos. 33-8216 and 34-47583. The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the " Exchange Act ") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated November 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Ionis Pharmaceuticals, Inc. Dated: November 6, 2024 By: /s/ Patrick R. O'Neil Patrick R. O'Neil Executive Vice President, Chief Legal Officer and General Counsel